Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for AUCinf.

Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for AUClast.

CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for CL/F.

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Cmax.

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for Tmax.

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for t1/2.

VzF is the apparent volume of distribution during terminal phase after oral / extravascular administration. VzF = Dose/(AUCinf × kel) where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Vz/F.

Fraction of unbound (not protein-bound) drug in plasma. Fu is determined using in vitro equilibrium dialysis method: concentration in buffer at equilibrium/concentration in plasma at equilibrium. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for Fu.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Ae96 = Sum of [urine concentration × sample volume] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Ae96.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Ae96% = Ae96 / Dose × 100 Ae96 = Sum of [urine concentration × sample volume] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Ae96.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for CLr.

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

The analysis population was defined as all treated participants.

An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

The analysis population was defined as all treated participants.

Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for AUCinf.

Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for AUClast.

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Cmax.

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for Tmax.

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for t1/2.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Ae96 = Sum of [urine concentration × sample volume] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Ae96.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for CLr.

Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for AUCinf.

Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for AUClast.

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Cmax.

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for Tmax.

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.

The analysis population was defined as all treated participants who had at least one concentration measurement for t1/2.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

Ae96 = Sum of [urine concentration × sample volume] for each collection interval from 0 to 96 hours post dose. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for Ae96.

Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.

CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for CLr.

Inhibition of Glucose Reabsorption = 100 * urinary glucose excretion / (eGFR(ML/MIN) * Weighted Mean Plasma Glucose * 0.0144). 0.0144 is a unit conversion factor used to make the ratio unitless. Geometric Coefficient of Variation was reported as a percent.

The analysis population was defined as all treated participants who had at least one concentration measurement for plasma glucose concentration.

Fluid balance = fluid intake - urine output.

The analysis population was defined as all treated participants who had at least one measurement for fluid balance.

Participants were asked to void at the end of each prescribed interval with forced voids prior to start and at the end of each interval.

The analysis population was defined as all treated participants who had at least one concentration measurement for UGE0-24hr.